Brain target occupancy of LY3372689, an inhibitor of the O‐GlcNAcase (OGA) enzyme, following administration of single and multiple doses to healthy volunteers

• Published in: Alzheimer's & dementia Vol. 17; no. S9
• Main Authors: Kielbasa, William, Shcherbinin, Sergey, Goldsmith, Paul, Phipps, Krista M, Biglan, Kevin, Mancini, Michele, Russell, David, Constantinescu, Cristian, Gunn, Roger N, Nuthall, Hugh Norman, Mergott, Dustin J., Lowe, Stephen L, Collins, Emily C
• Format: Journal Article
• Language: English
• Published: 01.12.2021

Background LY3372689, an O‐GlcNAcase (OGA) enzyme inhibitor, is being developed as a potential treatment of tauopathies, including Alzheimer’s disease. OGA inhibition is proposed to delay the progression of tau‐related diseases by slowing the accumulation of hyper‐phosphorylated, insoluble tau filam...